Modern approaches to anticoagulation therapy in patients after joint arthroplasty and intramedullary osteosynthesis of long bones of extremities. Clinical experience of using «Xarelto®»


  • Ilya Gaydarzhi
  • Vyacheslav Gorbenko
  • Sergey Tertishny
  • Yevgeny Korzh



rivaroxaban, deep venous thrombosis, pulmonary embolism, femur and tibia osteosynthesis


The efficacy of Rivaroxaban («Xarelto®») for preventing venous thromboembolism during the early postoperative period and outpatient treatment stage in patients after hip joint (70 cases) and knee joint (30 cases) arthroplasty, as well as intramedullary osteosynthesis (150 cases) for fractures of long bones of extremities, was assessed. The drug was used at a dose of 10 mg once a day, starting from 6–10 hours after the operation and up to 35 days. A high efficacy and safety of Rivaroxaban («Xarelto®») was revealed. An allergic response was registered in one patient.


Вырва О.Е. Сравнительная оценка эффективности ривароксабана и эноксапарина в профилактике тромбообразования после эндопротезирования тазобедренного сустава. Результаты исследований RECORD1 / О.Е. Вырва // Ортопед. травматол. — 2009. — № 3. — С. 97–100. — ISSN 0030-5987.

Eriksson B.I. Oral anticoagulants in development: focus on thromboprophylaxis in patient undergoing orthopedic surgery / B.I. Eriksson, D.J. Quinlan // Drugs. — 2006. — Vol. 66. —P. 1411–1429.

Rivaroxaban for thromboprophylaxis after orthopedic surgery: pooled analysis of two studies / W.D. Fisher, B.I. Eriksson, K.A. Bauer et al. // Thromb. Haemost. — 2007. — Vol. 97. — P. 931–937.

Медикаментозна терапія в схемі лікування хронічних захворювань вен нижніх кінцівок (рекомендації) // Актуальні питання ангіології. — 2009. — № 3 (4). — С. 22–30.

Паламарчук В.В., Булавин К.А. Опыт применения ривароксабана (КСАРЕ ЛТО®) при лечении переломов нижних конечностей / В.В. Паламарчук, К.А. Булавин // Ортопед. травматол. — 2010. — № 2. — С. 73–74. — ISSN 0030-5987.




Most read articles by the same author(s)